biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Stagliano's Neuron23 Raises Another $100 million

<< Previous

Bullboard Posts

Next >>

Comment by beenthereon Mar 30, 2022 8:04pm

110 Views

Post# 34561085

RE:RE:RE:RE:RE:Stagliano's Neuron23 Raises Another $100 million

I know it has something to do with BBB whatever that is!

And it has lost a lot of money for it's investors!

And hasn't been able to achieve anything in the last 10 years plus!

And it probably has the best do nothing management in the market!

Should I continue?

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December